Compare Ascendis Pharma A/S (ASND) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Vanguard Short Term Corporate Bond ETF — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Vanguard Short Term Corporate Bond ETF trades at $78.7. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ASND | VCSH | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Fixed Income |
52-Week High | $277.18 | $80.20 |
52-Week Low | $163.32 | $78.61 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
VCSH trades at $78.61, down 0.1% with a bearish technical outlook showing 16 sell signals versus 1 buy. The ETF maintains consistent dividend distributions with recent payments of $0.29-$0.30 per share. News coverage highlights VCSH's competitive expense ratio and yield advantages over comparable short-term bond ETFs, though institutional positions show mixed adjustments.
The short-term corporate bond ETF faces headwinds from the Fed's indication of no rate cuts in 2026, potentially limiting near-term upside. Current technical weakness suggests cautious positioning, though the neutral oscillator reading and institutional interest from firms like BlueSky Wealth Advisors provide some support. The primary risk remains interest rate sensitivity in the current monetary policy environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
